This essay pulls together a few threads from pieces I've written over the past months on my blog, where I dig into rabbit holes like GLP-1 economics among other things.

If the pharma side interests you, I just wrote up Novo's rise and fall as Europe's most valuable company:

https://philippdubach.com/posts/novo-was-europes-most-valuab...